Neolix Among First Approved for Autonomous Delivery Vehicle Trials in Malaysia, Accelerating Southeast Asia Expansion
Malaysia Greenlights Neolix as Part of the First Cohort Approved for Autonomous Delivery Sandbox Testing in One of Southeast Asia's Fastest-Growing High-Tech and Manufacturing Corridors KUALA LUMPUR, Malaysia, June 30, 2026 /PRNewswire/ -- Neolix, a...
World's First Solid Tumor CAR-T Approved: Jiahui International Cancer Center Provides Access for Patients Worldwide
SHANGHAI, June 24, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) welcomes the approval of Satri-cel (CT041, Kaileimei®), the world's first CAR-T cell therapy approved for the treatment of a solid tumor, marking a historic milestone...
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
BEIJING, June 1, 2026 /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical Group, has officially received marketing approval from the...
sweelin® Approved in Singapore as a Food Additive expanding Amai Proteins' Regulatory Footprint into Asia
Amai Proteins has achieved a major regulatory milestone with the Singapore Food Agency (SFA) approval of sweelin®, its flagship sweet protein, for use as a sweetening agent in food and beverage products. sweelin® is a next-generation sweet protein...
Cloopen Enters into Definitive Merger Agreement for Going-Private Transaction
BEIJING, May 12, 2026 /PRNewswire/ -- Cloopen Group Holding Limited (OTC: RAASY) ("Cloopen" or the "Company") today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with SpringX Holdings Limited,...
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
Minjuvi ® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory...
Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development
CHENGDU, China, April 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that following an application to The Stock Exchange of Hong Kong Limited (the "Stock...
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 4.803 Million Tokens, and Total Crypto and Total Cash Holdings of $11.4 Billion
Bitmine has been approved for uplisting to the New York Stock Exchange ("NYSE") from the NYSE American effective at the opening of trading on April 9, 2026 Bitmine has 3,334,637 staked ETH, representing $7.1 billion at $2,123 per ETH MAVAN (Made in...
3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a...